Orsiro™ Drug Eluting Stent in Routine Clinical Practice

N/ACompletedNCT02039739

Seung-Jung Park1,007 enrolled

Overview

The purpose of this study is to evaluate effectiveness and safety of Orsiro™ Drug Eluting Stent in Routine Clinical Practice

Study Type

OBSERVATIONAL

Enrollment

1,007

Conditions

Angioplasty, Transluminal, Percutaneous Coronary Coronary Artery Disease

Interventions

Orsiro™ Drug Eluting Stent groupDEVICE

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 20 and more * Intervention with Orsiro™ Drug Eluting Stent * Agreed with written informed consent form Exclusion Criteria: * Intervention with Orsiro™ drug eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock

Locations (18)

Hallym University Sacred Heart Hospital

Anyang, South Korea

Soon Chun Hyang University Hospital Bucheon

Bucheon-si, South Korea

Outcomes

Primary Outcomes

Composite event rate

Time frame: 1YEAR

Secondary Outcomes

ALL DEATH

Time frame: 5YEAR

CARDIAC DEATH

Time frame: 5YEAR

MYOCARDIAL INFARCTION

Time frame: 5YEAR

Composite event of death or myocardial infarction

Time frame: 5YEAR

Composite event of cardiac death or myocardial infarction

Time frame: 5YEAR

Target Vessel revascularization

Time frame: 5YEAR

Target Lesion revascularization

Time frame: 5YEAR

Stent thrombosis

stent thrombosis as classified by an Academic Research Consortium

Time frame: 5YEAR

Stroke

Time frame: 5YEAR

Procedural success

defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days.

Time frame: 3day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.